1
|
Ling C, Zhang Y, Li J, Chen W, Ling C. Clinical Use of Toxic Proteins and Peptides from Tian Hua Fen and Scorpion Venom. Curr Protein Pept Sci 2019; 20:285-295. [PMID: 29932034 DOI: 10.2174/1389203719666180622100641] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2018] [Revised: 04/10/2018] [Accepted: 05/22/2018] [Indexed: 12/16/2022]
Abstract
Traditional Chinese Medicine (TCM) has been practiced in China for thousands of years. As a complementary and alternative treatment, herbal medicines that are frequently used in the TCM are the most accepted in the Western world. However, animal materials, which are equally important in the TCM practice, are not well-known in other countries. On the other hand, the Chinese doctors had documented the toxic profiles of hundreds of animals and plants thousand years ago. Furthermore, they saw the potential benefits of these materials and used their toxic properties to treat a wide variety of diseases, such as heavy pain and cancer. Since the 50s of the last century, efforts of the Chinese government and societies to modernize TCM have achieved tremendous scientific results in both laboratory and clinic. A number of toxic proteins have been isolated and their functions identified. Although most of the literature was written in Chinese, this review provide a summary, in English, regarding our knowledge of the clinical use of the toxic proteins isolated from a plant, Tian Hua Fen, and an animal, scorpion, both of which are famous toxic prescriptions in TCM.
Collapse
Affiliation(s)
- Chen Ling
- Division of Cellular and Molecular Therapy, Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32611, Florida, FL, United States
| | - Yuanhui Zhang
- Department of Oncology, Baoshan Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Shanghai 201999, China
| | - Jun Li
- Division of Cellular and Molecular Therapy, Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32611, Florida, FL, United States.,Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
| | - Wenli Chen
- Department of Oncology, Baoshan Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Shanghai 201999, China
| | - Changquan Ling
- Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.,E-institute of Internal Medicine of Traditional Chinese Medicine, Shanghai Municipal Education Commission, Shanghai 201203, China
| |
Collapse
|
2
|
Li Z, Hu P, Wu W, Wang Y. Peptides with therapeutic potential in the venom of the scorpion Buthus martensii Karsch. Peptides 2019; 115:43-50. [PMID: 30858089 DOI: 10.1016/j.peptides.2019.02.009] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 02/20/2019] [Accepted: 02/27/2019] [Indexed: 12/18/2022]
Abstract
The scorpion Buthus martensii Karsch (BmK) has generated significant interest due to the presence of biologically active peptides in its venom. In the past decade, dozens of different peptides from BmK have been identified. Most of the peptides are neurotoxins and are responsible for the toxicity of BmK venom. Other peptides, including neurotoxins and non-disulfide-bridged peptides, show potential anticancer, antimicrobial, analgesic, and anti-epileptic therapeutic effects. These peptides are attractive candidates for drug development, and peptide derivatives have also been designed to enhance their therapeutic potential, such as ADWX-1 and Kn2-7. In this review, we provide an overview of the most promising peptides found in BmK venom and of modified peptide derivatives showing therapeutic potential.
Collapse
Affiliation(s)
- Zhongjie Li
- Medical College, Henan University of Science and Technology, Luoyang, 471003, China.
| | - Ping Hu
- Medical College, Henan University of Science and Technology, Luoyang, 471003, China
| | - Wenlan Wu
- Medical College, Henan University of Science and Technology, Luoyang, 471003, China
| | - Yong Wang
- Medical College, Henan University of Science and Technology, Luoyang, 471003, China
| |
Collapse
|
3
|
Bioanalytical method development and validation for determination of fibroblast growth factor peptide and its application to pharmacokinetic studies. Eur J Pharm Biopharm 2019; 135:83-93. [PMID: 30582960 DOI: 10.1016/j.ejpb.2018.12.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Revised: 11/22/2018] [Accepted: 12/20/2018] [Indexed: 01/10/2023]
Abstract
Fibroblast growth factor peptide (FGF-P) is a polypeptide analog of FGF-2 that could be a potential mitigation and treatment agent for radiation syndromes. Prior to conducting preclinical pharmacokinetics, we developed and validated the LC-MS/MS bioanalytical method for determination of FGF-P in rat plasma for the first time. FGF-P was extracted from rat plasma using the protein precipitation technique followed liquid-liquid extraction using dichloromethane as a solvent. The mobile phases consisted of two components: (a) 0.1% formic acid in water; and (b) acetonitrile: 0.1% formic acid in water (95:5) under gradient elution. The validated method was also successfully applied to a pharmacokinetic study of FGF-P (10 mg/kg, intravenous) in Wistar rats. The method proved to be specific, accurate, precise, and linear over the concentration range of 2-500 ng/mL with coefficient of determination greater than 0.99 in all validation batches. The within-run and between-run accuracy was 87.97-115.00% with a precision of less than 14%. The mean recoveries ranged from 88.14% to 101.73%. The stability of the compound in plasma samples was proven under various storage conditions. After intravenous administration of FGF-P (10 mg/kg) the C0 was 70.4 µg/mL and the AUC was 86.2 µg*min/mL.
Collapse
|
4
|
Zhu Y, Yang S, Wang J, Mao Y, Xu Y, An J, Huang Z. LC-MS/MS assay for the determination of a novel D-peptide antagonist of CXCR4 in rat plasma and its application to a preclinical pharmacokinetic study. J Pharm Biomed Anal 2018; 161:159-167. [PMID: 30165332 DOI: 10.1016/j.jpba.2018.08.032] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Revised: 08/13/2018] [Accepted: 08/15/2018] [Indexed: 11/25/2022]
Abstract
DV1 is a potent and selective D-peptide antagonist of CXCR4 and being developed as a novel drug candidate molecule. For preclinical pharmacokinetic study of DV1, we established an efficient and reliable liquid chromatography coupled to tandem mass spectrometric (LC-MS/MS) method for the assay of DV1 in rat plasma. Plasma samples were acidified by formic acid and then their protein content precipitated by acetonitrile. Sample separation was processed with a C18 column (4.6 mm × 100 mm, 5 μm) and washed by a water-acetonitrile gradient mobile phase containing 0.1% (v/v) formic acid at a flow rate of 0.4 mL/min. The mass spectrometer was operated in the multiple reaction monitoring mode and positive electrospray ionization. The assay had a good linearity over the range of 10-10000 ng/mL (r>0.998) for DV1. The adsorption of the peptide was diminished by organic additives during the quantitative procedure. The intra- and inter-day precision was 1.9-9.8% and the accuracy was 91.2-110.0%. No significant variation was observed under the optimized conditions. The recovery was above 52% with low matrix effects. The method was successfully applied to a pharmacokinetic study of DV1 after subcutaneous injection at dose of 10 mg/kg in rats. The half-life and AUCinf of DV1 were calculated as 8.7 h and 35,553 ng/mL·h, respectively. It is the first report on the quantitative analysis and pharmacokinetic characterization of a D-peptide targeted CXCR4, which should be useful for further preclinical studies and development of this and other peptide therapeutics.
Collapse
Affiliation(s)
- Yinsong Zhu
- School of Life Sciences, Tsinghua University, Beijing, China
| | - Shu Yang
- School of Life Sciences, Tsinghua University, Beijing, China
| | - Juan Wang
- School of Life Sciences, Tsinghua University, Beijing, China
| | - Yujia Mao
- School of Life Sciences, Tsinghua University, Beijing, China
| | - Yan Xu
- School of Life Sciences, Tsinghua University, Beijing, China.
| | - Jing An
- Department of Medicine, University of California at San Diego, La Jolla, CA, USA.
| | - Ziwei Huang
- School of Life Sciences, Tsinghua University, Beijing, China; Department of Medicine, University of California at San Diego, La Jolla, CA, USA.
| |
Collapse
|
5
|
Guo C, Guo XF, Zhao L, Chen DD, Wang J, Sun J. A Study on Immonium Ions and Immonium-Related Ions Depending on Different Collision Energies as Assessed by Q-TOF MS. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2018. [DOI: 10.1134/s1068162018040088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
6
|
Feng Y, Yin Z, Zhang D, Srivastava A, Ling C. Chinese Medicine Protein and Peptide in Gene and Cell Therapy. Curr Protein Pept Sci 2018; 20:251-264. [PMID: 29895243 DOI: 10.2174/1389203719666180612082432] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2018] [Revised: 04/10/2018] [Accepted: 05/22/2018] [Indexed: 01/05/2023]
Abstract
The success of gene and cell therapy in clinic during the past two decades as well as our expanding ability to manipulate these biomaterials are leading to new therapeutic options for a wide range of inherited and acquired diseases. Combining conventional therapies with this emerging field is a promising strategy to treat those previously-thought untreatable diseases. Traditional Chinese medicine (TCM) has evolved for thousands of years in China and still plays an important role in human health. As part of the active ingredients of TCM, proteins and peptides have attracted long-term enthusiasm of researchers. More recently, they have been utilized in gene and cell therapy, resulting in promising novel strategies to treat both cancer and non-cancer diseases. This manuscript presents a critical review on this field, accompanied with perspectives on the challenges and new directions for future research in this emerging frontier.
Collapse
Affiliation(s)
- Yinlu Feng
- Department of Traditional Chinese Medicine, 401 Hospital of the Chinese People's Liberation Army, Qingdao, Shandong 266071, China.,Division of Cellular and Molecular Therapy, Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32611, FL, United States
| | - Zifei Yin
- Division of Cellular and Molecular Therapy, Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32611, FL, United States
| | - Daniel Zhang
- Division of Cellular and Molecular Therapy, Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32611, FL, United States
| | - Arun Srivastava
- Division of Cellular and Molecular Therapy, Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32611, FL, United States
| | - Chen Ling
- Division of Cellular and Molecular Therapy, Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32611, FL, United States
| |
Collapse
|